Roberto Polakiewicz

Roberto Polakiewicz

Company: Cell Signaling Technology

Job title: Chief Scientific Officer


Interactive Panel Discussion & Q&A: De-risking Oncology Drug Discovery for Targeted Degradation 6:40 pm

Review how assay development and reagent selection can influence go- and no-go decisions prior to advancing a TPD or RNAi candidate into the clinic Discuss the challenges, strategies and best practices when it comes to confident results interpretation of efficacy and safety of drug candidates More speakers TBC!Read more

day: De-risking Drug Development to Ensure Success Before Entering the Clinic

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.